Daily Pill Shown to Double Survival Time for Highly Lethal Cancer in Clinical Trial

Pancreatic cancer kills more than 90% of the people it strikes. For decades, treatment options have amounted to variations on cytotoxic chemotherapy, with incremental gains measured in weeks. On May 31, 2026, researchers presented results from the RASolute 302 trial at the American Society of Clinical Oncology annual meeting in Chicago that broke that pattern: an oral pill called daraxonrasib nearly doubled median overall survival in patients with previously treated metastatic disease [1][2].

The data, published simultaneously in the New England Journal of Medicine, showed patients receiving daraxonrasib lived a median of 13.2 months compared to 6.7 months on standard chemotherapy — a hazard ratio of 0.40 that translates to a 60% reduction in the risk of death [3][4].

The Drug and Its Target

Daraxonrasib (also known as RMC-6236) is a RAS(ON) multi-selective inhibitor developed by Revolution Medicines, a South San Francisco-based biotechnology company. The drug targets RAS proteins in their active, GTP-bound state — a molecular target that researchers had pursued unsuccessfully for more than 40 years [5].

KRAS mutations drive approximately 90-95% of pancreatic ductal adenocarcinomas, making it one of the most genetically uniform cancers [6]. The most common variants are KRAS G12D (39.9% of cases), G12V (28.6%), and G12R (14.6%) [7]. Unlike earlier KRAS inhibitors such as sotorasib and adagrasib — which only work against the relatively rare G12C variant — daraxonrasib blocks multiple RAS variants simultaneously, making it applicable to the vast majority of pancreatic cancer patients [5].

What the Numbers Mean in Context

The headline claim of "doubling survival" requires context. In absolute terms, the median survival increased from 6.7 months to 13.2 months — a gain of approximately 6.5 months [3]. This is a second-line setting: all 500 patients in the trial had already failed at least one prior chemotherapy regimen for metastatic disease [4].

Source: RASolute 302 Phase 3 Trial / ASCO 2026

Data as of May 31, 2026CSV

For comparison, when gemcitabine was approved for pancreatic cancer in 1997, it improved median survival by roughly one month. The FOLFIRINOX regimen, introduced as first-line treatment, extended median survival to about 11 months from diagnosis. Daraxonrasib's 13.2-month median in the second-line setting — after patients had already progressed on chemotherapy — is therefore notable [2].

Progression-free survival also doubled: 7.2 months versus 3.6 months with chemotherapy. The objective response rate was 31.6% for daraxonrasib compared to 11.2% for chemotherapy in the overall population, and 33.2% versus 11.8% among patients with RAS G12 mutations specifically [4].

Trial Design and Rigor

RASolute 302 was a global, randomized, open-label Phase 3 trial conducted at more than 60 sites across North America, Europe, and Asia [8]. Five hundred patients with metastatic pancreatic ductal adenocarcinoma who had progressed on prior chemotherapy were randomized 1:1 to receive either oral daraxonrasib 300 mg once daily or investigator's choice of standard chemotherapy [3].

The co-primary endpoints were progression-free survival and overall survival in the RAS G12 mutation population. Key secondary endpoints included PFS and OS in the intent-to-treat population [3]. The trial met all primary and secondary endpoints with high statistical significance (p < 0.0001 for OS) [1].

The open-label design — where both patients and doctors know which treatment is being administered — is a legitimate point of scrutiny. Open-label trials can introduce bias in subjective endpoints, though overall survival is generally considered resistant to this problem because death is an objective outcome. The choice of investigator's-choice chemotherapy as the comparator arm reflects clinical reality in the second-line setting, where no single chemotherapy regimen is standard [9].

The trial enrolled patients regardless of specific KRAS mutation type, and the survival benefit was observed "regardless of RAS mutation status," though the primary analysis focused on the RAS G12 population [4].

Safety: Fewer Severe Side Effects Than Chemotherapy

One of the trial's more striking findings is that daraxonrasib appeared better tolerated than the chemotherapy it replaced. Grade 3 or higher treatment-related adverse events — the serious ones — occurred in 43.6% of patients on daraxonrasib versus 57.5% on chemotherapy [10].

The discontinuation rate tells a starker story: only 1.2% of patients stopped daraxonrasib due to side effects, compared to 11.2% who abandoned chemotherapy [10]. The most common adverse events with daraxonrasib were rash, oral inflammation, nausea, and diarrhea [4][8].

No new safety signals emerged compared to earlier Phase 1/2 data [4]. Formal quality-of-life data have not yet been publicly reported, though the lower rate of severe adverse events and the convenience of a once-daily oral pill versus intravenous chemotherapy infusions represent practical advantages for patients [8].

Who Funded This, and Who Profits

Revolution Medicines (NASDAQ: RVMD) funded and sponsored the trial. The company, which had a market capitalization of approximately $29 billion as of April 2026 despite generating no revenue, is a clinical-stage biotechnology firm focused exclusively on RAS-targeted therapies [11].

In a financing arrangement, Royalty Pharma agreed to provide up to $1.25 billion to Revolution Medicines in exchange for tiered royalties on worldwide net sales of daraxonrasib over 15 years [12]. Analysts project peak annual sales could exceed $7 billion [11].

No list price has been disclosed, as the drug has not yet received regulatory approval for commercial sale. For reference, existing targeted oral oncology drugs in the U.S. typically range from $15,000 to $25,000 per month. Given the projected sales figures and the patient population size, pricing will likely fall in this range or higher — a significant concern for access in health systems with constrained budgets [11].

The Path to Patients' Medicine Cabinets

The regulatory trajectory has moved unusually fast. Key milestones:

• October 2025: FDA granted Breakthrough Therapy designation and Orphan Drug designation [13]
• October 2025: FDA awarded a National Priority Voucher under the Commissioner's pilot program [13]
• April 28, 2026: Revolution Medicines requested expanded access [13]
• April 30, 2026: FDA issued "safe to proceed" letter for expanded access [13]
• May 1, 2026: Expanded access program opened; drug began shipping to eligible patients [14]

Revolution Medicines CEO Mark Goldsmith stated the company intends to submit a New Drug Application to the FDA "soon" [14]. The National Priority Voucher program provides an expedited review pathway, potentially shortening the typical 10-12 month review period.

For patients outside the United States, the timeline is less certain. Revolution Medicines has stated it will submit to "global regulatory authorities," but European Medicines Agency and other international reviews typically lag U.S. approval by 12-24 months. Patients in lower-income countries face additional barriers: the absence of generic competition during the patent period, limited oncology infrastructure for biomarker testing, and constrained pharmaceutical budgets that may not accommodate premium-priced targeted therapies [8].

The Scale of the Problem

Source: American Cancer Society / SEER

Data as of Jan 1, 2026CSV

Pancreatic cancer is projected to cause approximately 52,740 deaths in the United States in 2026, with 67,530 new diagnoses [15]. Globally, the disease kills roughly 466,000 people per year [16]. The five-year survival rate, while improved from 4.6% in 2000 to 11.5% today, remains among the lowest of any major cancer [15].

Not all pancreatic cancer patients would be eligible for daraxonrasib based on the RASolute 302 trial criteria. The trial enrolled patients with metastatic disease who had already failed first-line chemotherapy. Approximately 80% of pancreatic cancers are diagnosed at an advanced or metastatic stage, and most patients who receive first-line chemotherapy will eventually progress [15]. Based on KRAS mutation prevalence (>90%), the vast majority of progressing metastatic patients would be biologically eligible [6].

A separate trial, RASolute 303, is evaluating daraxonrasib in the first-line metastatic setting, which would substantially expand the eligible population if successful [9].

What Skeptics Are Watching

Several questions remain for the oncology community:

The open-label design means neither patients nor physicians were blinded to treatment assignment. While this is unlikely to affect overall survival measurement, it could influence decisions about when to discontinue treatment or pursue supportive care, potentially introducing subtle biases [9].

The control arm used investigator's choice chemotherapy rather than a single standardized regimen. This reflects real-world practice but introduces variability. If some patients in the control arm received suboptimal regimens, it could inflate the apparent benefit of daraxonrasib [9].

Crossover was not described in the available data. In oncology trials, patients randomized to the control arm sometimes cross over to receive the experimental drug after progression, which can complicate survival analyses. Whether crossover occurred — and how it was handled statistically — will be important to assess in the full publication [3].

Follow-up duration has not been explicitly stated in available disclosures. For a disease where median survival is measured in months, the maturity of the survival data will determine how robust the conclusions are.

Subgroup consistency is partially addressed: the benefit appeared to hold across RAS mutation subtypes and in the broader intent-to-treat population. However, detailed subgroup analyses by geography, prior treatment type, and performance status have not been fully disclosed [4].

The Research Landscape

Source: OpenAlex

Data as of Jan 1, 2026CSV

Scientific output on KRAS inhibitors for pancreatic cancer has surged over the past decade, peaking at over 7,300 publications in 2023. This reflects the broader effort to crack the "undruggable" RAS target — a goal that consumed billions in research funding over four decades before yielding clinically meaningful results.

Daraxonrasib is not alone in this space. Revolution Medicines is also developing RMC-9805, a KRAS G12D-specific inhibitor. Competitors include Mirati Therapeutics (now part of Bristol-Myers Squibb) and several other companies pursuing various RAS-targeting strategies. But daraxonrasib's multi-selective approach — hitting multiple RAS variants at once — gives it a broader patient population than mutation-specific drugs [5].

What This Means for Patients Now

For the roughly 50,000 Americans and hundreds of thousands worldwide who will die of pancreatic cancer this year, the RASolute 302 results offer something that has been absent from this disease: a treatment that produces a large, statistically unambiguous survival benefit with fewer side effects than the alternative.

The caveats are real. This is a second-line treatment for metastatic disease — not a cure. Median survival of 13.2 months means half of patients still died before that point. The drug is not yet commercially available outside of expanded access, its price is undisclosed, and global access will be uneven for years after approval [1][3][14].

But in a disease where the standard has been measured decline and palliative intent, an additional 6.5 months of life with a tolerable oral medication represents a meaningful change. Whether it proves to be a foundation for further progress — through combination regimens, earlier-line use, or adjuvant treatment — will depend on trials that are already underway [9].